Kucera H, Gerstner G, Pateisky N, Weghaupt K
Geburtshilfe Frauenheilkd. 1983 Feb;43(2):107-11. doi: 10.1055/s-2008-1037069.
In a retrospective study the data of 79 patients undergoing radiation-therapy for recurrent endometrial cancer during the years 1972-1978 were evaluated. Group I consisted of 43 patients, who primarily underwent irradiation, group II consisted of 36 patients, who primarily underwent surgery (total abdominal hysterectomy) mostly without irradiation. All patients were primarily classified as FIGO-stage I, the median age was 69 and 67 years respectively. In 32 cases (74%) of group I the localisation of the recurrence was the uterus, in 8 (19%) the vagina and in 3 (7%) the small pelvis. In group II a vaginal recurrence was found in 25 patients (69%), in 11 (31%) a pelvic recurrence. In two thirds of all cases the recurrences were diagnosed within three years of the primary treatment. Late recurrences after 5 years occurred in group I in 10%, in group II twice as often. The treatment of all recurrences was irradiation. 54 patients (68%) died within 2 years, 25 survived their recurrence for more than 2 years, (32%). In group I 23% survived for more than 2 years, in group II 42%. At the time of performance of the study the 5-year-survival-rate is 13%. Thus in two thirds of patients we succeeded in extending the survival for at least 2 years. The prognosis of a recurrence following surgery is distinctly better than following primary intracavitary irradiation. 56% of vaginal recurrences following primary surgery survived more than 2 years. The 5-year-survival-rate was similar in these vaginal recurrences however to the uterine recurrences following primary irradiation. The prognosis of patients undergoing primary surgery was the better, the later the recurrence occurred.
在一项回顾性研究中，对1972年至1978年间接受复发性子宫内膜癌放射治疗的79例患者的数据进行了评估。第一组由43例主要接受放疗的患者组成，第二组由36例主要接受手术（全腹子宫切除术）且大多未接受放疗的患者组成。所有患者最初均被归类为国际妇产科联盟（FIGO）I期，中位年龄分别为69岁和67岁。第一组中32例（74%）复发部位在子宫，8例（19%）在阴道，3例（7%）在小骨盆。第二组中25例（69%）发现阴道复发，11例（31%）盆腔复发。在所有病例的三分之二中，复发在初次治疗后三年内被诊断出来。第一组中5年后出现晚期复发的比例为10%，第二组的发生率是其两倍。所有复发患者均接受了放疗。54例患者（68%）在2年内死亡，25例患者（32%）复发后存活超过2年。第一组中23%的患者存活超过2年，第二组为42%。在进行这项研究时，5年生存率为13%。因此，在三分之二的患者中，我们成功地将生存期延长了至少2年。手术后复发的预后明显优于初次腔内放疗后复发的预后。初次手术后阴道复发的患者中有56%存活超过2年。然而，这些阴道复发的5年生存率与初次放疗后子宫复发的5年生存率相似。初次手术患者的预后越好，复发发生得越晚。
